Study #2023-0441
A multi-center, open-label, phase I study to evaluate the safety, tolerability, pharmacokinetics and preliminary antitumor activity of Pan-RAS inhibitor YL-17231 in patients with advanced solid tumors harboring mutations in KRAS, HRAS, or NRAS
MD Anderson Study Status
Enrolling
Treatment Agent
YL-17231
Description
This study will evaluate the safety, tolerability, drug levels, pharmacodynamic effects, and clinical activity of YL 17231 in patients with advanced solid tumors harboring mutations in KRAS, HRAS, or NRAS.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Advanced Solid Tumors
Study phase:
Phase I
Physician name:
David Sanghyun Hong
Department:
Investigational Cancer Therapeutics
For general questions about clinical trials:
1-888-994-0731
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.